Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation by Daniel Kaemmerer et al.
TRANSPLANTATION 
RESEARCH
Kaemmerer et al. Transplantation Research 2012, 1:7
http://www.transplantationresearch.com/content/1/1/7RESEARCH Open AccessTreatment of bone loss in patients with chronic
liver disease awaiting liver transplantation
Daniel Kaemmerer1*, Benjamin Schmidt3, Gabriele Lehmann2, Gunter Wolf2, Utz Settmacher3
and Merten Hommann1Abstract
Background: Most of the patients awaiting liver transplantation already have osteopenia or even osteoporosis by
end-stage liver disease.
In a retrospective study, we investigated the effect of pre-treatment with oral monthly ibandronate (150 mg),
vitamin D3 (800 IU/day) and calcium (1 g/day) for osteopenia and osteoporosis caused by end-stage liver disease in
patients before and after liver transplantation (LT).
Methods: The bone mineral density (BMD) of the lumbar spine (LS) and the femoral neck was measured
prospectively pre- and post-LT in 31 patients with existing pre-transplant osteopenia. Patients had osteopenia of
the LS prior to LT (T-score −1.8 ± 1.5) so that the treatment medication was initiated immediately after
the diagnosis.
Results: The study group showed a permanently increased BMD with significant differences (g/cm²) from baseline
up to 12 months post LT at the lumbar spine (LS: pre-LT 0.80 ± 0.11 g/cm², three months: 0.90 ± 0.08 (P<0.005);
six months: 0.95 ± 0.11 (P< 0.008); 12 months: 1.00 ± 0.09 -0.85 (P<0.012).
Conclusion: The combined pre- and post-operative treatment with oral ibandronate had significantly improved
bone mineral density of the lumbar spine at 3, 6 and 12 months post LT. The immediate post-operative bone loss
after LT can be significantly avoided by pre-treatment of liver transplant candidates affected by osteopenia.
Keywords: Bone mineral density, Osteoporosis, Ibandronate, Liver transplantation, Chronic liver diseaseBackground
Numerous patients have osteoporosis before transplant-
ation as a result of their underlying chronic hepatic disease.
The reported numbers range from 12% up to a consider-
able 55%, depending on the study [1-4]. With respect to
the frequency of bone fractures in chronic liver disease, the
reports range from 3% to 35% [5-7]. The type of osteopor-
osis in chronic liver disease cannot be determined clearly,
as aspects of ‘low turnover’ osteoporosis as well as charac-
teristics of ‘high turnover’ osteoporosis have been reported
[5,8]. It has been demonstrated that the bone status before
transplantation is a predictive factor for the bone mineral
loss after liver transplantation (LT) [9]. Low bone mineral
density (BMD) values at the time of evaluation for* Correspondence: Daniel.Kaemmerer@zentralklinik.de
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crease the risk of suffering further BMD loss after LT. The
first three to six months after transplantation are associated
with the greatest loss of BMD [10-13]. The probability of
bone fractures in the course of the post-transplant period
has been reported as ranging from 6% to 65% [14-17]. Stud-
ies which initiate treatment at the time of osteopenia diagno-
sis prior to transplantation are missing to date.
We present our results of a retrospective study for the
evaluation of an oral monthly dose of ibandronate as an
immediate bisphosphonate treatment of pre-existing
osteopenia in patients awaiting LT who were followed-
up for up to 24 months after LT.Patients and methods
Patients with chronic liver disease who underwent LT be-
tween May 2006 and December 2008 at the University
Hospital Jena were enrolled. Informed consent wasntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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approval was given by the local committee. All patients
underwent a BMD measurement of the lumbar spine
(LS L1-L4) and of the femoral neck (FN) with dual-X-
ray-absorptiometry (DEXA, Lunar Prodigy Advance/Nar-
row Fan, General Electric, USA) during their evaluation for
LT and post-operatively at three, six, 12 and 24 months.
Laboratory tests of bone metabolism parameters (bone-
specific alkaline phosphatase (BAP), pyridinoline (PYD),
and deoxypyridinoline (DPYD)) were performed at the
same points in time. The study group consisted of 31
patients (age: 54.1± 9.5 years, Table 1) who had osteopenia
at the LS at the time of evaluation (a densiometric T-score
lower −1.5).
T-score is a comparison of a patient’s BMD to a
healthy, young reference group with the same sex and
ethnicity. Osteopenia is defined as a BMD T-score be-
tween −1.0 and −2.5 and osteoporosis as a T-score below
−2.5 standard deviations below the mean peak bone
mass. In these patients, the treatment (oral monthly IBA
150 mg, vitamin D3 800 IE and calcium 1000 mg daily)
was started before LT (an average of 18 months before
LT). Immunosuppression after LT was managed as quad-
ruple induction with steroid, tacrolimus, mycophenolate
mofetil and basiliximab. Afterwards, treatment was indi-
vidualized. Except in patients with an underlying auto-
immune disease, steroid withdrawal was attempted in all
patients within the first six months post-LT.
Laboratory tests
At the time of evaluation for LT as well as three, six, 12
and 24 months after transplantation, the following la-
boratory parameters were measured: serum bone-specific
alkaline phosphatase (8 to 16.6 μg/l), early morning urin-
ary excretion PYD (95 to 215 μg/g creatinine), and DPYD




Female/male 9 / 22
Liver disease cholestatic:2
non-cholestatic:29
T-score lumbar spine( 0 – -1
normal range)
-1.77±1.51
T-score femoral neck -1.21±1.24




(95 – 215 μg/g creatinine)
311±180
Desoxypridinoline
(15 – 45 μg/g creatinine)
46.01±28.2
IBA, ibandronate.Fracture analysis
X-ray and computed tomography checks were routinely
performed before LT to rule out pre-existing fractures.
In the follow-up period, X-ray and computed tomog-
raphy were performed in cases of clinical symptoms with
regard to bone fractures or in cases of bone densio-
metric suspicion of a bone fracture. Fracture information
was taken from patient records as well as by phone
interviews after 24 months post-LT.
Statistical analyses
Primary endpoints were changes in bone mineral density
of the LS at 3, 6, 12 and 24 months post-LT. Occurrence
of bone fractures and changes in the bone mineral dens-
ity of the FN were considered as secondary endpoints.
Primary endpoints were changes in BMD of the LS at
three, six, 12 and 24 months post-LT. Occurrence of
bone fractures and changes in the bone mineral density
of the FN were considered as secondary endpoints.All
parameters were initially checked with the Kolmogorov-
Smirnov adjustment test for normal distribution. The
BMD differences and the laboratory parameters were
analyzed by paired or un-paired t-test, Mann–Whitney
test or Wilcoxon test depending on the status of the
normal distribution.
Results
The patient characteristics of the groups are presented
in Table 1.
Bone mineral density measurement
The BMD measurements are presented in Table 2.
At the LS the study group showed a consistently sig-
nificant increase in BMD from three to 12 months (T-
scores and g/cm²). With regard to baseline, we observed
a significant BMD rise of T-scores from three to 24
months. The g/cm² data demonstrated a persistent rise
in BMD but without significant differences at FN.
Bone fractures
Within 24 months follow-up after transplantation, there
was one osteoporosis-associated pathological bone frac-
ture (1/31; 3.2%) without corresponding trauma. There
was one vertebral body fracture and no extravertebral
fractures.
Laboratory test results
Bone specific alkaline phosphatase, Pyridinoline, and
Deoxypyridinoline
The laboratory chemistry parameters are shown in
Table 3.
The study group noted elevated levels of PYD, DPYD
and BAP before transplantation. PYD values were above
the normal range and slowly declined up to 12 months
Table 2 Bone mineral density of the lumbar spine and femoral neck
T-scores P-value T-score vs.
Pre-LT




Spine L1-L4 Pre-TX -1.77±1.51 - 0.80±0.11 - -
3 months -1.31±1.52 0.001 0.90±0.08 0.005 13.59±12.32
6 months -1.02±1.53 0.005 0.95±0.11 0.008 17.10±12.68
12 months -0.85±1.18 0.005 1.00±0.09 0.012 18.78±14.98
24 months -0.87±1.11 0.08 1.03±0.10 0.068 24.26±15.61
Femoral neck Pre-TX -1.21±1.24 - 0.74±0.14 - -
3 months -1.22±1.19 0.001 0.75±0.10 0.929 3.11±9.30
6 months -1.32±1.09 0.001 0.83±0.13 0.443 5.08±10.06
12 months -1.24±0.80 0.001 0.85±0.10 0.450 3.31±10.05
24 months -1.30±0.64 0.002 0.93±0.09 0.783 2.72±12.83
LT, liver transplantion; TX, transplantation.
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directly after LT.
Discussion
In this study, we have evaluated the effect of an oral
bisphosphonate ibandronate, vitamin D3 and calcium
treatment for the treatment of preexisting osteopenia
and osteoporosis in patients awaiting liver transplant-
ation. As far as we are aware, this is the first study to
clinically evaluate the use of pre-treatment with ibandro-
nate before LT. Osteopenia and osteoporosis in patients
with end-stage liver disease is a well known clinical
problem, frequently associated with cholestatic diseases
but also found in patients with hepatitis C, alcoholic
liver disease and even hemochromatosis as reasons for
LT [2,18].
We have demonstrated that monthly ibandronate
treatment (150 mg orally) in combination with calcium
(1000 mg) and vitamin D3 (800 IU) is a promising treat-
ment approach for the reduction of post-transplant
osteopenia and osteoporosis after LT. At none of the
measurement points in time post-operatively, were there
BMD losses in the LS and FN.
In the pre-treated group, we saw marked BMD
increases, in particular at the LS but also at the FN;
however, BMD increased to a lesser extent in the FN. It
was possible for the first time, to modulate the immedi-
ate post-operative BMD loss in favor of a marked BMD
increase (LS: three months: 13.6%, six months: 17.1%;
FN: three months: 3.1%, six months: 5.1%) by initial
ibandronate treatment at the time of the evaluation for
liver transplantation.
Bone mineral density measurements
Different studies have been published on the treatment
of BMD loss in patients with chronic liver diseases.
Intravenous as well as oral bisphosphonates have beenproven to be effective in chronic liver diseases and after
LT but with marked qualitative differences. Most of the
studies focus on patients with primary biliary cirrhosis
(PBC) as one entity for chronic liver diseases which
could be treated by LT [5,8]. PBC-associated bone loss
can be significantly improved by alendronate compared
to placebo, as shown by Zein et al. [19]. In a study by
Guanabens et al. alendronate was proven to be more ef-
fective in reducing bone loss than treatment with etidro-
nate [20]. The greater antiresorptive power has been
shown to be one reason for the higher efficacy of
alendronate.
Our study confirms the efficacy of ibandronate for in-
creasing BMD at the LS, as has been reported by several
previous studies [21-23]. Ibandronate and zoledronate
are bisphosphonates with the highest antiresorptive po-
tential which could result in such high bone increases as
reported by our data and the data of Bodingbauer et al.
up to 24 months after LT [24]. Many studies have shown
that the BMD loss is highest during the first three to six
months after transplantation. This is particularly evident
at the spine. It correlates also with the incidence of ver-
tebral body fractures shortly after LT [17,25]. It shows
the need for sufficient bone loss protection during the
first months after LT. In contrast to a review by Kasturi
et al. [26] who found bisphosphonate use did not result
in a statistically significant change in BMD at the end of
the first year after LT, our study shows a significantly
permanent increase up to 12 months post-LT at the LS
for the T-scores as well as the percentage measurements
(g/cm²).
Pre-treatment with ibandronate has shown an excel-
lent and highly significant BMD increase at the LS and
the FN, particularly during the critical immediate post-
operative period. Post-operative ibandronate treatment
was proven to be effective and BMD increases were
recorded. These results were confirmed by Wagner D et al.
Table 3 Pyridinoline (PYD μg/g creatinine) and Deoxypyridinoline (DPYD μg/g creatinine), Bone specific alkaline
phosphatase (BAP μg/l).
PYD(μg/g creatinine) IBA P-value vs. Pre-LT DPYD(μg/g creatinine) IBA P-value vs. Pre-LT
Pre-LT 311±180 - Pre-L 46.1±28.2 -
3 months 301±118 0.51 3 months 35.4±14.0 0.44
6 months 317±146 0.31 6 months 42.8±19.5 0.49
12 months 220±62 0.18 12 months 33.4±17.4 0.75
24 months 169±54 0.18 24 months 32.2±15.6 0.65
BAP(μg/l) IBA p-value vs. Pre-LT
Pre-LT 18.6±8.7 -
3 months 10.0±3.9 0.016*
6 months 12.2±3.9 0.022*
12 months 14.9±5.8 0.08
24 months 15.0±7.7 0.63
IBA, ibandromate; LT, liver transplantation.
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cantly lower rate of fractures after ibandronate treat-
ment [27].
In a randomized controlled prospective trial, Boding-
bauer et al. showed the effectiveness of a prophylactic
bisphosphonate treatment with zolendronate during the
first 12 months after LT [24]. They not only reported on
high elevated BMDs, they also proved the potency of
fracture reduction. This study underlines our data with
ibandronate. We have shown highly elevated bone min-
eral density at the LS and FN and only reported one
fracture during the course of the investigation. In our
study, the prevalence of bone fractures was 3.2%. This
result seems to confirm the efficacy of ibandronate for
the reduction of bone fractures after LT as does the
prevalence of bone fractures in 7.4% of the patients in
the study of our group before ibandronate intravenously
2.0 mg every three months [28]. It has to be recognized,
however, that this study is retrospective, underpowered
and not designed for proving a decrease of fractures
post-LT. It became evident that the bone status before
LT is an important predictive factor for the loss of BMD
after LT. Low BMD values at the time of evaluation for
LT or previous bone fractures increase the risk of suffer-
ing further BMD loss after LT [9]. The early treatment
of osteopenia and osteoporosis increases the BMD and
avoids the decline caused by immobilization, high ster-
oid and calcineurin-inhibitory medication during the
first months post-LT. The question about the limitation
of post transplant fractures has to be proven in further
studies with an adequate number of cases.
Laboratory tests
The study group showed an increased BAP activity prior to
treatment initiation with ibandronate/vitamin D/calcium.
The vitamin D status at the time of evaluation for LT wasunknown and this is a limitation of the study. As it is
known that a vitamin D deficiency is frequently observed
in patients with chronic liver failure [29], this may be
assumed with a high probability as being the cause of the
increased BAP activity. There was a reduction of the BAP
activity in due course in the study group, even though this
was less pronounced. This may reflect a reduced bone
turnover under the influence of ibandronate and it may be
the result of the mineralization promoting effect of vitamin
D treatment. As for DPYD, there is no certain anti-
resorptive effect on the bone turnover evident, contrary to
our expectations. These findings are in agreement with the
results of an investigation by Bodingbauer et al. who did
not find any dynamic of the investigated markers of bone
turnover, except for a reduction of osteocalcine [24].
Conclusions
The combined pre- and postoperative treatment with oral
ibandronate significantly improved bone mineral density of
the LS at at 3,6 and 12 months post-LT. The immediate
post-operative bone loss after LT can be significantly
avoided by pre-treatment of transplant candidates affected
by osteopenia.
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